MabThera licensed in CLL

MabThera (rituximab) is now indicated for use in combination with chemotherapy for the first-line treatment of chronic lymphocytic leukaemia (CLL).

The recommended dose for the new indication is 375mg/m2 by iv infusion on day one of first treatment cycle, prior to chemotherapy, then 500mg/m2 on day one of subsequent cycles for a total of six cycles.

View MabThera drug record

Further information: Roche

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in